Dull quarter with stable margin

Extended Winter and continued weak demand drags volume

In Q4FY24, demand for FMCG products faced ongoing challenges, dampening volume growth. There was no meaningful change in the rural growth trends. Factors, such as low farm income and the rise of small regional competitors, are adversely affecting larger companies. A delayed Winter is likely to impact seasonal categories, such as beverages. We note Chyawanprash sales lost steam in Q3, due to delayed Winter and have not recovered in Q4. Food categories continue to outperform home and personal care products. Reviving rural demand is crucial for the FMCG sector, with companies pinning hopes on a favourable Monsoon, which could stimulate the rural economy.

FMCG universe to report low single-digit value and volume growth

We expect our FMCG coverage universe to report revenue and volume growth of 2.8% YoY and 3.6% YoY, respectively, in Q4FY24E with a fivevear CAGR of 8.8% vs 9.0% in Q3FY24. In Q4, companies such as, BECTORS, TATACONS, CLGT, and JYL saw stronger revenue growth. Regional firms, particularly in sectors, such as biscuits and laundry, continue to challenge larger competitors due to favourable commodity prices. This fierce competition is dragging companies such as HUVR and BRIT. However, JYL and BECTORS stand to gain from enhanced distribution. VBL and DABUR might encounter hurdles from slow beverage demand in the domestic market, due to a delayed Winter. TATACONS' growth stems from robust performance in new ventures, increased volume in salt, and the acquisition of Capital Foods. CLGT is expected to achieve high single-digit growth through aggressive promotional offers in modern trade and premiumization while for GCPL we estimate double-digit growth in the domestic business, aided by Raymond Consumer Care (RCC) acquisition (ex-RCC ~3% YoY).

Most key RM are stable

In Q4, essential commodities, such as crude and palm oil, have witnessed a sequential increase. However, it has not been significant to impact margin as YoY growth remains subdued. Companies focus have been focused on offering higher schemes to drive volume and there have been no incremental price cuts.

Margin to remain in a same range as in Q3

For Q4FY24E, we expect gross margin expansion of 185bp YoY and flat QoQ (ex-ITC, up 260bp YoY & flat QoQ), and EBITDA margin gains of 20bp YoY but flat QoQ (ex-ITC, up 80bp YoY and flat QoQ), led by benign input prices, partly offset by higher spend on advertising. <u>We expect our</u> <u>FMCG coverage universe to post EBITDA growth of 3.5% YoY (ex-ITC growth of 7.2% YoY).</u> Except for BRIT, ITC, BECTORS and HUVR, which could experience a decline in EBITDA margin, other companies are expected to achieve margin expansion. Companies, such as CLGT, NEST, GCPL and DABUR, are anticipated to achieve margin expansion exceeding 250bp YoY.

Our preferred picks are Mrs. Bectors, Godrej Consumer and Tata Consumer.



3 April 2024

| Price performance (%) | ЗМ | 6M | 12M |
|------------------------------|--------|------------|--------|
| Nifty | 4.3 | 14.9 | 28.9 |
| Hindustan Unilever | (13.1) | (8.3) | (10.7) |
| ITC | (10.9) | (3.3) | 12.9 |
| Nestle India | (4.1) | 14.4 | 29.6 |
| Varun Beverages | 20.4 | 59.0 | 108.7 |
| Britannia Industries | (8.0) | 7.5 | 11.8 |
| Godrej Consumer Products | 1.8 | 19.8 | 23.3 |
| Tata Consumer Products | 3.2 | 28.4 | 56.1 |
| Dabur India | (3.6) | (4.1) | (3.0) |
| Marico | (8.7) | (13.8) | 3.4 |
| Colgate Palmolive | 12.3 | 41.5 | 83.7 |
| Emami | (19.4) | (18.0) | 21.6 |
| Jyothy Labs | (7.9) | 21.0 | 136.6 |
| Mrs Bectors Food Specialties | (4.3) | 7.8 | 97.4 |
| Bajaj Consumer Care | 3.1 | 0.3 | 51.7 |
| Source: Bloomberg | | | |
| Company | Reven | ue (INR mr | ר) |

| Compony | Revenue (INR mn) | | | | | | |
|---|-----------------------|---------|---------|--|--|--|--|
| Company | FY24E | FY25E | FY26E | | | | |
| Hindustan Unilever | 606,370 | 651,109 | 713,991 | | | | |
| ITC | 686,117 | 736,584 | 800,661 | | | | |
| Nestle India | 190,211 | 205,242 | 227,157 | | | | |
| Dabur India | 127,875 | 139,382 | 152,213 | | | | |
| Britannia Industries | 168,269 | 183,353 | 201,840 | | | | |
| Godrej Consumer Products | 140,672 | 152,599 | 169,808 | | | | |
| Varun Beverages | 160,426 | 207,621 | 256,145 | | | | |
| Tata Consumer Products | 152,791 | 181,011 | 199,324 | | | | |
| Marico | 95,987 | 103,911 | 113,194 | | | | |
| Colgate Palmolive | 56,565 | 61,210 | 66,159 | | | | |
| Emami | 35,682 | 39,088 | 43,053 | | | | |
| Jyothy Labs | 28,120 | 31,201 | 34,436 | | | | |
| Bajaj Consumer Care | 9,831 | 10,623 | 11,582 | | | | |
| Mrs Bectors Food | 16,330 | 19,135 | 22,419 | | | | |
| Specialities | 10,550 | 17,155 | 22,117 | | | | |
| Company | Adjusted PAT (INR mn) | | | | | | |
| company | FY24E | FY25E | FY26E | | | | |
| Hindustan Unilever | 103,012 | 112,619 | 124,894 | | | | |
| ITC | 194,329 | 214,539 | 237,980 | | | | |
| Nestle India | 30,044 | 35,724 | 40,342 | | | | |
| Dabur India | 19,625 | 21,938 | 24,572 | | | | |
| Britannia Industries | 21,187 | 23,483 | 25,887 | | | | |
| Godrej Consumer Products | 19,601 | 23,874 | 28,429 | | | | |
| Varun Beverages | 20,559 | 27,271 | 34,565 | | | | |
| Tata Consumer Products | 15,833 | 17,119 | 21,732 | | | | |
| Marico | 14,477 | 15,985 | 17,721 | | | | |
| Colgate Palmolive | 13,263 | 14,677 | 16,171 | | | | |
| Emami | 7,887 | 8,695 | 9,809 | | | | |
| Jyothy Labs | 3,965 | 4,504 | 5,015 | | | | |
| | 1,616 | 1,761 | 1,956 | | | | |
| Bajaj Consumer Care Mrs Bectors Food | 1,010 | ., | | | | | |

Note: *Nestle & Varun Beverages' valuation ratios are for CY22E, CY23E and CY24E, pricing as on 3 April 2024 Source: Company, Elara Securities Estimate

Key financials

| | | Reve | enue (INR n | nn) | | | | EE | ITDA (IN | R mn) | | | | Adjuste | d net pro | fit (INR m | ın) | |
|----------------------------------|-------------|------------|-------------|------------|------------|-----------------------|-------------|------------|------------|------------|------------|-----------------------|-------------|------------|------------|------------|------------|-----------------------|
| Company | Q4 FY24E | Q3 FY24 | Q4 FY23 | QoQ (%) | YoY (%) | 5-year CAGR (%) | Q4 FY24E | Q3 FY24 | Q4 FY23 | QoQ (%) | YoY (%) | 5-year CAGR (%) | Q4 FY24E | Q3 FY24 | Q4 FY23 | QoQ (%) | YoY (%) | 5-year CAGR (%) |
| Hindustan Unilever | 148,740 | 151,880 | 148,930 | (2.1) | (0.1) | 8.4 | 33,901 | 35,400 | 34,710 | (4.2) | (2.3) | 7.9 | 25,410 | 25,410 | 24,710 | 0.0 | 2.8 | 9.8 |
| ITC | 166,400 | 164,833 | 163,980 | 1.0 | 1.5 | 6.8 | 61,010 | 60,243 | 62,094 | 1.3 | (1.7) | 5.9 | 53,209 | 55,721 | 50,140 | (4.5) | 6.1 | 9.9 |
| Nestle India | 50,641 | 45,836 | 48,084 | 10.5 | 5.3 | 11.2 | 12,770 | 10,697 | 10,476 | 19.4 | 21.9 | 13.2 | 8,992 | 7,629 | 7,366 | 17.9 | 22.1 | 14.2 |
| Dabur India | 28,650 | 32,551 | 26,778 | (12.0) | 7.0 | 6.1 | 5,104 | 6,678 | 4,098 | (23.6) | 24.5 | 2.2 | 3,851 | 5,142 | 3,118 | (25.1) | 23.5 | (2.9) |
| Britannia Industries | 41,088 | 42,563 | 40,232 | (3.5) | 2.1 | 8.0 | 7,595 | 8,211 | 8,009 | (7.5) | (5.2) | 11.7 | 5,139 | 5,593 | 5,587 | (8.1) | (8.0) | 11.8 |
| Godrej Consumer Products | 32,323 | 36,596 | 32,002 | (11.7) | 1.0 | 5.7 | 7,320 | 8,407 | 6,409 | (12.9) | 14.2 | 4.8 | 5,122 | 5,880 | 4,743 | (12.9) | 8.0 | 4.6 |
| Varun Beverages | 41,368 | 26,677 | 38,930 | 55.1 | 6.3 | 24.9 | 8,808 | 4,183 | 7,980 | 110.6 | 10.4 | 32.2 | 4,622 | 1,320 | 4,291 | 250.2 | 7.7 | NA |
| Tata Consumer Products | 39,890 | 38,039 | 36,187 | 4.9 | 10.2 | 17.6 | 5,965 | 5,724 | 5,117 | 4.2 | 16.6 | 27.9 | 3,624 | 3,704 | 2,750 | (2.2) | 31.8 | 63.2 |
| Marico | 22,700 | 24,220 | 22,400 | (6.3) | 1.3 | 7.1 | 4,349 | 5,130 | 3,930 | (15.2) | 10.7 | 9.0 | 3,176 | 3,830 | 3,020 | (17.1) | 5.2 | 8.3 |
| Colgate Palmolive | 14,500 | 13,864 | 13,417 | 4.6 | 8.1 | 4.8 | 5,338 | 4,592 | 4,430 | 16.2 | 20.5 | 12.0 | 3,828 | 3,301 | 3,181 | 16.0 | 20.4 | 13.7 |
| Emami | 8,775 | 9,963 | 8,360 | (11.9) | 5.0 | 6.5 | 2,103 | 3,149 | 1,998 | (33.2) | 5.2 | 6.3 | 1,756 | 2,877 | 1,835 | (39.0) | (4.3) | 7.7 |
| Jyothy Labs | 6,680 | 6,775 | 6,170 | (1.4) | 8.3 | 5.3 | 1,133 | 1,186 | 913 | (4.5) | 24.2 | 6.9 | 866 | 909 | 590 | (4.7) | 46.7 | 3.3 |
| Bajaj Consumer Care | 2,385 | 2,358 | 2,445 | 1.2 | (2.5) | -0.1 | 382 | 373 | 421 | 2.5 | (9.2) | (11.9) | 380 | 376 | 410 | 1.0 | (7.3) | (7.4) |
| Mrs Bectors Food Specialities | 4,050 | 4,289 | 3,461 | (5.6) | 17.0 | NA | 571 | 612 | 482 | (6.7) | 18.3 | NA | 318 | 346 | 277 | (8.2) | 14.9 | NA |

Source: Company, Elara Securities Estimate

Peer valuation

| C | Tieleer | Datia a | Мсар | CMP | ТР | Upside | | P/E (x) | | EV/ | 'EBITDA | (x) | | ROE (%) | |
|-------------------------------|--------------------|------------|----------|-------|-------|--------|-------|---------|-------|-------|---------|-------|-------|---------|-------|
| Company | Ticker | Rating | (INR bn) | (INR) | (INR) | (%) | FY24E | FY25E | FY26E | FY24E | FY25E | FY26E | FY24E | FY25E | FY26E |
| Hindustan Unilever | HUVR IN | Reduce | 5,324 | 2,266 | 2,600 | 15 | 51.7 | 47.3 | 42.6 | 36.6 | 33.7 | 30.6 | 20.7 | 22.9 | 25.9 |
| ITC | ITC IN | Accumulate | 5,309 | 425 | 490 | 15 | 27.3 | 24.7 | 22.3 | 20.6 | 19.0 | 17.1 | 28.9 | 32.2 | 35.7 |
| Nestle India* | NEST IN | Accumulate | 2,463 | 2,555 | 2,720 | 6 | 82.0 | 69.0 | 61.1 | 55.9 | 47.5 | 42.1 | 108.2 | 101.5 | 91.0 |
| Varun Beverages* | VBL IN | Accumulate | 1,918 | 1,476 | 1,463 | (1) | 93.3 | 70.3 | 55.5 | 54.4 | 41.8 | 33.7 | 34.2 | 32.7 | 31.2 |
| Godrej Consumer Products | GCPL IN | Buy | 1,221 | 1,194 | 1,400 | 17 | 62.3 | 51.1 | 43.0 | 42.6 | 35.6 | 30.2 | 14.1 | 16.3 | 17.6 |
| Britannia Industries | BRIT IN | Reduce | 1,165 | 4,835 | 4,940 | 2 | 55.0 | 49.6 | 45.0 | 37.3 | 33.8 | 30.3 | 48.9 | 41.6 | 35.1 |
| Tata Consumer Products | TATACONS IN | Accumulate | 1,067 | 1,120 | 1,246 | 11 | 67.4 | 64.2 | 50.6 | 45.7 | 36.4 | 30.8 | 8.8 | 7.8 | 8.8 |
| Dabur India | DABUR IN | Accumulate | 941 | 531 | 596 | 12 | 47.9 | 42.9 | 38.3 | 37.8 | 34.1 | 30.5 | 20.5 | 20.2 | 19.9 |
| Colgate Palmolive | CLGT IN | Accumulate | 762 | 2,800 | 2,675 | (4) | 57.4 | 51.9 | 47.1 | 40.0 | 36.4 | 33.1 | 74.9 | 75.3 | 71.2 |
| Marico | MRCO IN | Accumulate | 642 | 496 | 580 | 17 | 44.2 | 40.0 | 36.1 | 31.3 | 28.6 | 26.0 | 36.2 | 36.0 | 35.8 |
| Emami | HMN IN | Accumulate | 192 | 438 | 565 | 29 | 24.3 | 22.0 | 19.5 | 19.5 | 17.3 | 15.2 | 32.9 | 32.6 | 31.4 |
| Jyothy Labs | JYL IN | Reduce | 164 | 446 | 540 | 21 | 41.3 | 36.4 | 32.7 | 32.4 | 28.7 | 25.7 | 23.4 | 23.1 | 22.4 |
| Mrs Bectors Food Specialities | BECTORS IN | Buy | 66 | 1,127 | 1,414 | 25 | 47.1 | 38.3 | 31.9 | 27.6 | 22.8 | 19.1 | 22.9 | 22.4 | 21.6 |
| Bajaj Consumer Care | BAJAJCON IN | Buy | 33 | 233 | 270 | 16 | 20.6 | 18.9 | 17.0 | 16.7 | 15.0 | 13.1 | 19.9 | 20.4 | 21.2 |

Note: *Nestle and Varun Beverages valuation ratios are for CY23, CY24 and CY25, pricing as on 3 April 2024; TP and Ratings are as per our last published note Source: Elara Securities Estimate

ElaraCapital

Coverage History



| | Date | Rating | Target Price | Closing Price |
|----|-----------------|------------|--------------|----------------------|
| 5 | 8-Feb-2023 | Buy | INR 640 | INR 495 |
| 6 | 26-May- 2023 | Buy | INR 852 | INR 717 |
| 7 | 2-Jun-2023 | Accumulate | INR 852 | INR 779 |
| 8 | 7-Aug-2023 | Accumulate | INR 1,106 | INR 944 |
| 9 | 10-Nov-2023 | Accumulate | INR 1,414 | INR 1,217 |
| 10 | 8-Feb-2024 | Buy | INR 1,414 | INR 1,142 |
| | | | | |



| | Date | Rating | Target Price | Closing Price | | |
|-------------------|-------------|------------|--------------|---------------|--|--|
| 24 | 31-Jan-2023 | Accumulate | INR 1,050 | INR 913 | | |
| 25 | 28-Apr-2023 | Accumulate | INR 963 | INR 908 | | |
| 26 | 11-May-2023 | Accumulate | INR 1,050 | INR 983 | | |
| 27 | 2-Jun-2023 | Reduce | INR 1,050 | INR 1,061 | | |
| 28 | 7-Aug-2023 | Accumulate | INR 1,120 | INR 1,031 | | |
| 29 | 20-Dec-2023 | Accumulate | INR 1,230 | INR 1,050 | | |
| 30 | 31-Jan-2024 | Buy | INR 1,400 | INR 1,164 | | |
| AC=Analyst change | | | | | | |



| | Date | Rating | Target Price | Closing Price |
|----|-------------|------------|--------------|----------------------|
| 5 | 3-Feb-2023 | Accumulate | INR 785 | INR 727 |
| 6 | 26-Apr-2023 | Accumulate | INR 822 | INR 747 |
| 7 | 19-Jun-2023 | Accumulate | INR 933 | INR 857 |
| 8 | 27-Jul-2023 | Accumulate | INR 963 | INR 850 |
| 9 | 31-Oct-2023 | Accumulate | INR 1,030 | INR 901 |
| 10 | 19-Jan-2024 | Accumulate | INR 1,246 | INR 1,147 |

Guide to Research Rating

| BUY | Absolute Return >+20% |
|------------|-----------------------------|
| ACCUMULATE | Absolute Return +5% to +20% |
| REDUCE | Absolute Return -5% to +5% |
| SELL | Absolute Return < -5% |



Disclosures & Confidentiality for non U.S. Investors

The Note is based on our estimates and is being provided to you (herein referred to as the "Recipient") only for information purposes. The sole purpose of this Note is to provide preliminary information on the business activities of the company and the projected financial statements in order to assist the recipient in understanding / evaluating the Proposal. Nothing in this document should be construed as an advice to buy or sell or solicitation to buy or sell the securities of companies referred to in this document. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. Nevertheless, Elara Securities (India) Private Limited or any of its affiliates is committed to provide independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Elara Securities (India) Private Limited or any of its affiliates have not independently verified all the information given in this Note and expressly disclaim all liability for any errors and/or omissions, representations or warranties, expressed or implied as contained in this Note. The user assumes the entire risk of any use made of this information, Elara Securities (India) Private Limited or any of its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for or solicit investment banking or other business from any company referred to in this Note. Each of these entities functions as a separate, distinct and independent of each other. This Note is strictly confidential and is being furnished to you solely for your information. This Note should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This Note is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Elara Securities (India) Private Limited or any of its affiliates to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. Upon request, the Recipient will promptly return all material received from the company and/or the Advisors without retaining any copies thereof. The Information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This Information is subject to change without any prior notice. Elara Securities (India) Private Limited or any of its affiliates reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Elara Securities (India) Private Limited is under no obligation to update or keep the information current. Neither Elara Securities (India) Private Limited nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. This Note should not be deemed an indication of the state of affairs of the company nor shall it constitute an indication that there has been no change in the business or state of affairs of the company since the date of publication of this Note. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Elara Securities (India) Private Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Any clarifications / queries on the proposal as well as any future communication regarding the proposal should be addressed to Elara Securities (India) Private Limited. It is important to note that any dispute with respect to this research report, would not have access to stock exchange investor redressal forum or arbitration mechanism.

Elara Securities (India) Private Limited was incorporated in July 2007 as a subsidiary of Elara Capital (India) Private Limited.

Elara Securities (India) Private Limited is a SEBI registered Stock Broker in the Capital Market and Futures & Options Segments of National Stock Exchange of India Limited [NSE], in the Capital Market Segment of BSE Limited [BSE] and a Depository Participant registered with Central Depository Services (India) Limited [CDSL].

Elara Securities (India) Private Limited's business, amongst other things, is to undertake all associated activities relating to its broking business.

The activities of Elara Securities (India) Private Limited were neither suspended nor has it defaulted with any stock exchange authority with whom it is registered in last five years. However, during the routine course of inspection and based on observations, the exchanges have issued advise letters or levied minor penalties on Elara Securities (India) Private Limited for minor operational deviations in certain cases. Elara Securities (India) Private Limited has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has the certificate of registration been cancelled by SEBI at any point of time.

Elara Securities (India) Private Limited offers research services primarily to institutional investors and their employees, directors, fund managers, advisors who are registered or proposed to be registered.

Details of Associates of Elara Securities (India) Private Limited are available on group company website www.elaracapital.com

Elara Securities (India) Private Limited is maintaining arms-length relationship with its associate entities.

Research Analyst or his/her relative(s) may have financial interest in the subject company. Elara Securities (India) Private Limited does not have any financial interest in the subject company, whereas its associate entities may have financial interest. Research Analyst or his/her relative does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Elara Securities (India) Private Limited does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Associate entities of Elara Securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities (India) Private Limited may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report. Research Analyst or his/her relative or Elara Securities (India) Private Limited or its associate entities does not have any other material conflict of interest at the time of publication of the Research Report.

Research Analyst or his/her relative(s) has not served as an officer, director or employee of the subject company.

Research analyst or Elara Securities (India) Private Limited have not received any compensation from the subject company in the past twelve months. Associate entities of Elara Securities (India) Private Limited may have received compensation from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities have not managed or co-managed public offering of securities for the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities do recompany entry twelve months. Research analyst or Elara Securities (India) Private Limited or its associate shave not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months. Research analyst or Elara Securities (India) Private Limited or its associate entities may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company or third party in connection with the Research Report in the past twelve months.

Disclaimer & Standard warning

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.



Disclaimer for non U.S. Investors

The information contained in this note is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

Disclaimer for U.S. Investors

This material is based upon information that we consider to be reliable, but Elara Capital Inc. does not warrant its completeness, accuracy or adequacy and it should not be relied upon as such.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. Prices, values or income from any securities or investments mentioned in this report may fall against the interests of the investor and the investor may get back less than the amount invested. Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate. Where an investment or security is denominated in a different currency to the investor's currency of reference, changes in rates of exchange may have an adverse effect on the value, price or income of or from that investment to the investor. The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or source and, if necessary, seek professional advice.

Certain statements in this report, including any financial projections, may constitute "forward-looking statements." These "forward-looking statements" are not guarantees of future performance and are based on numerous current assumptions that are subject to significant uncertainties and contingencies. Actual future performance could differ materially from these "forward-looking statements" and financial information.

Elara Securities (India) Private Limited



Access our reports on Bloomberg: Type RESP ESEC <GO>

Also available on Thomson & Reuters

ElaraCapital

Elara Securities (India) Private Limited

Registered Office Address: One International Center, Tower 3, 21st Floor, Senapati Bapat Marg, Elphinstone Road (West) Mumbai – 400 013, India Tel : +91 22 6164 8500 CIN: U74992MH2007PTC172297 | SEBI Research Analyst Registration No.: INH000000933 Member of BSE Limited and National Stock Exchange of India Limited | SEBI REGN. NO.: INZ 000 238236 Member of Central Depository Services (India) Limited | SEBI REGN. NO.: IN-DP-370-2018 Investor Grievance Email ID: investor.grievances@elaracapital.com - Tel. +91 22 6164 8509 Compliance Officer: Mr. Anand Rao - Email ID: anand.rao@elaracapial.com